Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (5): 942-945. doi: 10.19723/j.issn.1671-167X.2024.05.031

Previous Articles    

仁珍 管1,2, 士刚 丁1, 岩岩 石3, 艳 薛1,*()   

  • Received:2022-11-26 Online:2024-10-18 Published:2024-10-16
  • Contact: 艳 薛 E-mail:xueyanby@163.com
  • Supported by:
    the Clinical Cohort Construction Program of Peking University Third Hospital and the Key Clinical Projects of Peking University Third Hospital(BYSY2017026)

RICH HTML

   

PDF (PC)

CLC Number: 

  • R573.1

Table 1

Comparison of Hp eradication rate in patients of different age and gender"

Category Eradication failure Eradication successful Total Eradication rate/% χ2 P value
Gender 0.002 0.961
  Male 83 1 981 2 064 96.0
  Female 89 2 108 2 197 95.9
Age/years 0.046 0.830
   < 60 141 3 378 3 519 96.0
  ≥60 31 711 742 95.8

Table 2

Comparison of Hp eradication rate in different proton pump inhibitor groups"

Section Example number Eradication failure Eradication successful Eradication rate/%
Group A 383 14 369 96.3
Group B 1 461 60 1 401 95.7
Group C 1 841 78 1 763 95.7
Group D 576 20 556 96.5
χ2value 0.826
P value 0.843

Table 3

Comparison of Hp eradication rate in different antibiotic combination groups"

Antibiotic group Example number Eradication failure Eradication successful Eradication rate/%
Group a 1 067 21 1 046 98.0
Group b 2 544 131 2 413 94.8
Group c 188 9 179 95.2
Group d 179 2 177 98.9
Group e 230 11 219 95.2
Group f 53 0 53 100.0
Fisher value 28.436
P value < 0.001

Table 4

Comparison of Hp eradication rates among different proton pump inhibitor groups and different antibiotic combinations"

Group Antibiotic group Example number Eradication failure Eradication successful Eradication rate/% χ2value P value
Group A Group a 87 1 86 98.8 5.071 0.024
Group b 201 16 185 92.0
Group B Group a 374 9 365 97.6 4.448 0.035
Group b 874 44 830 95.0
Group C Group a 351 8 343 97.7 4.783 0.029
Group b 1 243 62 1 181 95.0
Group D Group a 255 3 252 98.8 3.878 0.049
Group b 226 9 217 96.0
1 吕秋菊, 蒲强红. CYP2C19基因多态性对含左氧氟沙星方案根除幽门螺杆菌疗效影响的Meta分析[J]. 中国医药导刊, 2017, 19 (11): 1174- 1180.
doi: 10.3969/j.issn.1009-0959.2017.11.026
2 刘文忠, 谢勇, 陆红, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 中华消化杂志, 2017, 37 (6): 364- 378.
doi: 10.3760/cma.j.issn.0254-1432.2017.06.002
3 Nagy P , Johansson S , Molloy-Bland M . Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA[J]. Gut Pathog, 2016, 8, 8.
doi: 10.1186/s13099-016-0091-7
4 Cai Q , Zhu C , Yuan Y , et al. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: A nationwide multicentre study[J]. Gut, 2019, 68 (9): 1576- 1587.
doi: 10.1136/gutjnl-2018-317556
5 Bakhti SZ , Latifi-Navid S , Zahri S . Unique constellations of five polymorphic sites of Helicobacter pylori vacA and cagA status associated with risk of gastric cancer[J]. Infect Genet Evol, 2020, 79, 104167.
doi: 10.1016/j.meegid.2019.104167
6 Bartpho TS , Wattanawongdon W , Tongtawee T , et al. Precan-cerous gastric lesions with Helicobacter pylori vacA+/babA2+/oipA+ genotype increase the risk of gastric cancer[J]. Biomed Res Int, 2020, 2020, 7243029.
7 Sugano K , Tack J , Kuipers EJ , et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64 (9): 1353- 1367.
doi: 10.1136/gutjnl-2015-309252
8 Graham DY , Lu H , Yamaoka Y . A report card to grade Helicobacter pylori therapy[J]. Helicobacter, 2007, 12 (4): 275- 278.
doi: 10.1111/j.1523-5378.2007.00518.x
9 张建中. 中国幽门螺杆菌治疗低根除率现状及应对策略[J]. 胃肠病学和肝病学杂志, 2017, 26 (6): 637- 639.
doi: 10.3969/j.issn.1006-5709.2017.06.005
10 李一凡, 胡庆林, 费繁荣, 等. 深圳市17 589例体检人群中幽门螺杆菌分型结果分析[J]. 国际检验医学杂志, 2021, 42 (16): 1921- 1924.
doi: 10.3969/j.issn.1673-4130.2021.16.001
11 Mamori S , Higashida A , Kawara F , et al. Age-dependent eradication of Helicobacter pylori in Japanese patients[J]. World J Gastroenterol, 2010, 16 (33): 4176- 4179.
doi: 10.3748/wjg.v16.i33.4176
12 Meyer JM , Silliman NP , Wang W , et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999[J]. Ann Intern Med, 2002, 136 (1): 13- 24.
doi: 10.7326/0003-4819-136-1-200201010-00008
13 Liang X , Xu X , Zheng Q , et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study[J]. Clin Gastroenterol Hepatol, 2013, 11 (7): 802- 807.
doi: 10.1016/j.cgh.2013.01.008
14 Chen Q , Zhang W , Fu Q , et al. Rescue therapy for Helicobacter pylori eradication: A randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy[J]. Am J Gastroenterol, 2016, 111 (12): 1736- 1742.
doi: 10.1038/ajg.2016.443
15 Bai P , Zhou LY , Xiao XM , et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients[J]. J Dig Dis, 2015, 16 (8): 464- 470.
doi: 10.1111/1751-2980.12271
16 Zhang YX , Zhou LY , Song ZQ , et al. Primary antibiotic resis-tance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: A prospective serial study[J]. World J Gastroenterol, 2015, 21 (9): 2786- 2792.
doi: 10.3748/wjg.v21.i9.2786
No related articles found!
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd